Các bài nghiên cứu mới về VACCINE COVID-19

Thứ năm - 20/08/2020 23:34
|In ra
|Đóng cửa sổ này

Cục Thông tin KH&CN quốc gia trân trọng kính gửi đến các nhà khoa học những nghiên cứu về vắc xin COVID-19 trên thế giới. Đây là những bài viết đã được xuất bản chính thức hoặc được chấp nhận đăng trên những cơ sở dữ liệu học thuật chính thống. Những nghiên cứu công bố có liên quan tới COVID-19 khác được tổng hợp tại đường link cuối bài.

SCIENCEDIRECT

1. Determinants of COVID-19 vaccine acceptance in the US

E Clinical MedicineIn press, corrected proof, Available online, 12 August 2020, Article 100495

Amyn A. Malik, SarahAnn M. McFadden, Jad Elharake, Saad B. Omer

https://www.sciencedirect.com/science/article/pii/S258953702030239X/pdfft?md5=9c784f3166a95195ac289b0707f9656b&pid=1-s2.0-S258953702030239X-main.pdf

2. Approaches and Challenges in SARS-CoV-2 Vaccine Development

Cell Host & Microbe, In press, corrected proof, Available online, 10 August 2020

Gabriel Dagotto, Jingyou Yu, Dan H. Barouch

https://www.sciencedirect.com/science/article/pii/S1931312820304558/pdfft?md5=4be29e651c20deffefe5ad146d0029a5&pid=1-s2.0-S1931312820304558-main.pdf

3. The effect of Bacillus Calmette–Guérin (BCG) vaccination in preventing sever infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic

Vaccine, In press, corrected proof, Available online, 10 August 2020

Kiddus Yitbarek, Gelila Abraham, Tsinuel Girma, Tizta Tilahun, Mirkuzie Woldie

https://www.sciencedirect.com/science/article/pii/S0264410X20310495/pdfft?md5=0408fdcbf25f0d5b36e1161f6403f65a&pid=1-s2.0-S0264410X20310495-main.pdf

4. Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.?

Infectious Disease Modelling, In press, journal pre-proof, Available online, 6 August 2020

Enahoro Iboi, Calistus N. Ngonghala, Abba B. Gumel

https://www.sciencedirect.com/science/article/pii/S2468042720300300/pdfft?md5=294670b24af5a5aaf42dcaede8bb01ef&pid=1-s2.0-S2468042720300300-main.pdf

5. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2

Infection, Genetics and Evolution, In press, journal pre-proof, Available online, 1 August 2020, Article 104490

Navpreet Kaur, Rimaljot Singh, Zahid Dar, Rakesh Kumar Bijarnia, Tanzeer Kaur

https://www.sciencedirect.com/science/article/pii/S156713482030321X/pdfft?md5=5de22c13dbaa3e297ba256e3e8253f09&pid=1-s2.0-S156713482030321X-main.pdf

6. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet, 15–21 August 2020, Volume 396, Issue 10249, Pages 479-488

Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Wei Chen

https://www.sciencedirect.com/science/article/pii/S0140673620316056/pdfft?md5=e4ead7a7865a001118ee875497bcb04e&pid=1-s2.0-S0140673620316056-main.pdf

7. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The Lancet, 15–21 August 2020, Volume 396, Issue 10249, Pages 467-478

Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, Brian Angus, Oxford COVID Vaccine Trial Group

https://www.sciencedirect.com/science/article/pii/S0140673620316044/pdfft?md5=d40a9f24fd6cc27425fef0bf10b8b28f&pid=1-s2.0-S0140673620316044-main.pdf

8. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Cell, 6 August 2020, Volume 182, Issue 3, Pages 713-721.e9

Hui Wang, Yuntao Zhang, Baoying Huang, Wei Deng, Xiaoming Yang

https://www.sciencedirect.com/science/article/pii/S0092867420306954/pdfft?md5=72cdc013725efd6e81f34f5202069cfd&pid=1-s2.0-S0092867420306954-main.pdf

SPRINGER NATURE

1. Mobile Virology Research and Diagnostic Laboratory (MVRDL: BSL-3) for COVID-19 Screening, Virus Culturing and Vaccine Development

Yellamanchali Sreenivas Rao in Transactions of the Indian National Academy of Engineering (2020)

https://link.springer.com/content/pdf/10.1007%2Fs41403-020-00150-6.pdf

2. Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy

Nimisha Roy, Jyoti Kashyap, Deepti Verma… in Transactions of the Indian National Academ… (2020)

https://link.springer.com/content/pdf/10.1007%2Fs41403-020-00148-0.pdf

3. Animal Models to Study Emerging Technologies Against SARS-CoV-2

Jhinuk Basu Mullick, Chelsey S. Simmons… in Cellular and Molecular Bioengineering (2020)

https://link.springer.com/content/pdf/10.1007%2Fs12195-020-00638-9.pdf

4. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?

Varsha Singh in Current Nutrition Reports (2020)

https://link.springer.com/content/pdf/10.1007%2Fs13668-020-00330-4.pdf

5. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19

Rashi Jain, Somdutt Mujwar in Structural Chemistry (2020)

https://link.springer.com/content/pdf/10.1007%2Fs11224-020-01605-w.pdf

6. 1H, 13C, and 15N backbone chemical shift assignments of the apo and the ADP-ribose bound forms of the macrodomain of SARS-CoV-2 non-structural protein 3b

F. Cantini, L. Banci, N. Altincekic, J. K. Bains… in Biomolecular NMR Assignments (2020)

https://link.springer.com/content/pdf/10.1007%2Fs12104-020-09973-4.pdf

7. Radiological findings spectrum of asymptomatic coronavirus (COVID-19) patients

Rasha Mostafa Mohamed Ali… in Egyptian Journal of Radiology and Nuclear … (2020)

https://link.springer.com/content/pdf/10.1186%2Fs43055-020-00266-3.pdf

8. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach

Ashish M. Kanhed, Dushyant V. Patel, Divya M. Teli, Nirav R. Patel… in Molecular Diversity (2020)

https://link.springer.com/content/pdf/10.1007%2Fs11030-020-10130-1.pdf

PUBMED

1. Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection

Jasvinder Singh Bhatti, Gurjit Kaur Bhatti, Naina Khullar, Arubala P. Reddy, P. Hemachandra Reddy

Mol Neurobiol. 2020 Aug 18 : 1–22.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431281/pdf/12035_2020_Article_2074.pdf

2. COVID-19 Vaccine: A comprehensive status report

Simran Preet Kaur, Vandana Gupta

Virus Res. 2020 Aug 13 : 198114.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423510/pdf/main.pdf

3. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes

Asaf Poran, Dewi Harjanto, Matthew Malloy, Christina M. Arieta, Daniel A. Rothenberg, Divya Lenkala, Marit M. van Buuren, Terri A. Addona, Michael S. Rooney, Lakshmi Srinivasan, Richard B. Gaynor

Genome Med. 2020; 12: 70. Published online 2020 Aug 13.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425796/pdf/13073_2020_Article_767.pdf

4. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein

Ahmed Rakib, Saad Ahmed Sami, Nusrat Jahan Mimi, Md. Mustafiz Chowdhury, Taslima Akter Eva, Firzan Nainu, Arkajyoti Paul, Asif Shahriar, Abu Montakim Tareq, Nazim Uddin Emon, Sajal Chakraborty, Sagar Shil, Sabrina Jahan Mily, Taibi Ben Hadda, Faisal A. Almalki, Talha Bin Emran

Comput Biol Med. 2020 Sep; 124: 103967. Published online 2020 Aug 13.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423576/pdf/main.pdf

5. SARS‐CoV‐2 replicating in nonprimate mammalian cells probably have critical advantages for COVID‐19 vaccines due to anti‐Gal antibodies: A minireview and proposals

Ji‐Ming Chen

J Med Virol. 2020 Aug 2 : 10.1002/jmv.26312.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404575/pdf/JMV-9999-na.pdf

6. COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

D. Baker, C. A. K. Roberts, G. Pryce, A. S. Kang, M. Marta, S. Reyes, K. Schmierer, G. Giovannoni, S. Amor

Clin Exp Immunol. 2020 Aug 1 : 10.1111/cei.13495.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/pdf/CEI-9999-na.pdf

7. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2

Navpreet Kaur, Rimaljot Singh, Zahid Dar, Rakesh Kumar Bijarnia, Neelima Dhingra, Tanzeer Kaur

Infect Genet Evol. 2020 Aug 1 : 104490.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395230/pdf/main.pdf

8. Strong immunity in the early two years of age links to frequent immunization of routine vaccines

Li Qiu, Chengdong Zhang, Junbo Wu, Jie Luo, Mihai G. Netea, Zhiguo Luo, Qibin Leng

Sci Bull (Beijing) 2020 Aug 8

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414308/pdf/main.pdf

9. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru, Gabriel Ozorowski, Hannah L. Turner, Aleksandar Antanasijevic, Deli Huang, Xiaoning Wang, Jonathan L. Torres, Jolene K. Diedrich, Jing-Hui Tian, Alyse D. Portnoff, Nita Patel, Michael J. Massare, John R. Yates, III, David Nemazee, James C. Paulson, Greg Glenn, Gale Smith, Andrew B. Ward

Version 1. bioRxiv. Preprint. 2020 Aug 6.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418715/pdf/nihpp-2020.08.06.234674.pdf

10. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development

Christine Grady, Seema Shah, Franklin Miller, Marion Danis, Marie Nicolini, Jorge Ochoa, Holly Taylor, Dave Wendler, Annette Rid

Vaccine. 2020 Aug 11

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418641/pdf/main.pdf

11. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein

William R. Martin, Feixiong Cheng

Version 1. ChemRxiv. Preprint. 2020 Aug 7.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418723/pdf/nihpp-12770225.pdf

12. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy

Lorenzo Palamenghi, Serena Barello, Stefania Boccia, Guendalina Graffigna

Eur J Epidemiol. 2020 Aug 17 : 1–4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431109/pdf/10654_2020_Article_675.pdf

13. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Wanbo Tai, Xiujuan Zhang, Aleksandra Drelich, Juan Shi, Jason C. Hsu, Larry Luchsinger, Christopher D. Hillyer, Chien-Te K. Tseng, Shibo Jiang, Lanying Du

Cell Res. 2020 Aug 5 : 1–4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403570/pdf/41422_2020_Article_387.pdf

14. COVID-19: Is there a role for Western blots and skin testing for determining immunity and development of a vaccine?

Charles S. Pavia, Gary P. Wormser

Diagn Microbiol Infect Dis. 2020 Aug 13 : 115148.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424330/pdf/main.pdf

15. Sex-Based Vaccine Response in the Context of COVID-19

Patricia Robin McCartney

J Obstet Gynecol Neonatal Nurs. 2020 Aug 5

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405769/pdf/main.pdf

16. Vero cell upstream bioprocess development for the production of viral vectors and vaccines

Sascha Kiesslich, Amine A. Kamen

Biotechnol Adv. 2020 Nov 15; 44: 107608.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405825/pdf/main.pdf

17. The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region

Justin R Ortiz, Joanie Robertson, Jui-Shan Hsu, Stephen Yu, Amanda Driscoll, Sarah Williams, Wilbur Chen, Meagan Fitzpatrick, Samba Sow, Robin J Biellik, Jean-Marie Okwo-Bele, Kathleen Neuzil

Version 1. medRxiv. Preprint. 2020 Aug 14.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430629/pdf/nihpp-2020.08.13.20147595.pdf

18. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

Alexandra C. Walls, Brooke Fiala, Alexandra Schäfer, Samuel Wrenn, Minh N. Pham, Michael Murphy, Longping V. Tse, Laila Shehata, Megan A. O'Connor, Chengbo Chen, Mary Jane Navarro, Marcos C. Miranda, Deleah Pettie, Rashmi Ravichandran, John C. Kraft, Cassandra Ogohara, Anne Palser, Sara Chalk, E-Chiang Lee, Elizabeth Kepl, Cameron M. Chow, Claire Sydeman, Edgar A. Hodge, Brieann Brown, Jim T. Fuller, Kenneth H. Dinnon, Lisa E. Gralinski, Sarah R. Leist, Kendra L. Gully, Thomas B. Lewis, Miklos Guttman, Helen Y. Chu, Kelly K. Lee, Deborah H. Fuller, Ralph S. Baric, Paul Kellam, Lauren Carter, Marion Pepper, Timothy P. Sheahan, David Veesler, Neil P. King

Version 1. bioRxiv. Preprint. 2020 Aug 12.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430571/pdf/nihpp-2020.08.11.247395.pdf

19. Vaccine optimization for COVID-19, who to vaccinate first?

Laura Matrajt, Julie Eaton, Tiffany Leung, Elizabeth R Brown

Version 1. medRxiv. Preprint. 2020 Aug 15.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430607/pdf/nihpp-2020.08.14.20175257.pdf